MORE HERE:
Roy Baynes, the chief medical officer at Merck Research Laboratories, said that a 302-patient study of molnupiravir in people with Covid-19 who have not been hospitalized has shown signs of benefit for the drug.
The percentage of patients who were hospitalized or died in the treatment groups was lower than in the placebo group, but Merck said “the number of events reported are not sufficient to provide a meaningful measure of clinical effect.”
Baynes said the medicine showed “a very clear antiviral effect.” Actual data will be presented at a medical meeting.
Oh goodie.
More poison
great now you need multiple vaccines AND a pill
This sounds no different than the drug combination protocols that other doctors have been using such as Ivermectin+ and HCQ+. Give them to people within 5 days of diagnosis or symptoms.
But there is no money to be made on those drugs. So nobody funded a large study of them. Notice that they dropped the study on in-patient/hospitalized patients, and shortened it to 5 days from 7 days for symptomatic out patients only. Exactly the same protocol for the other drugs which the FDA refuses to endorse and many pharmacists refuse to fill.
Many of the “trials” that TPTB used to try to debunk HCQ+ and Ivermectin+ were done on hospitalized and ICU patients, and did not combine them with the minerals, vitamins and antibiotics. Merck is playing the hand TPTB dealt them.
You'll be able to spot the virtue signalers by their walk and constant virtue-whining.
Big Pharma has $$$o much to gain from the Scamdemic.
Meanwhile,HCQ and Ivermectin pills should be in gumball machines everywhere,for $0.50 each. No scrip needed.
Ping to post 7.